HansaBioMed Life Sciences and Finnish Red Cross Blood Service start a join effort for developing next generation of Extracellular Vesicles from donated blood as reference material for researchers

The new cooperation is set under the heads of agreement and is aimed to offer highly characterized and standardized EV material for life science market to further accelerate the development of the EV applications in diagnostics and therapy.

Tallinn, Estonia, 18 January 2022.

HansaBioMed Life Sciences, is the oldest company entirely focused on the research and development of products in the field extracellular vesicles (EVs). Today, HansaBioMed collaborates with various international groups, both Academic and Industrial, and participates in research projects aimed to implement the knowledge on the full potential of the EVs. Together with the research activities, HansaBioMed provides its customers with high quality of products dedicated to the Extracellular Vesicles and nanoparticle research.

“The current reference material available for the researchers in the field of Extracellular Vesicles requires constant improvement and implementation. The collaboration with an experienced blood center, as the FRCBS, is aimed to achieve a next generation of EVs from blood components, highly characterized and standardized both in preanalytical processing of the raw material and downstream EV purification. The final product will be an useful support for researchers working on understanding of the potential of blood derived EVs” says Dr Paolo Guazzi COO, HansaBioMed.

Finnish Red Cross Blood Service (FRCBS) is the nationwide blood service provider in Finland and has been performing active scientific research for more than 60 years. R&D activity can be divided into strategic focus areas: the effectiveness of the blood supply chain, new cell therapy treatments and the development of tissue transplants. FRCBS holds a solid position in developing EV-based technologies with its partner network and is now exploring the possibilities to find partners to manufacture EVs isolated from blood components such as erythrocytes, platelets and plasma.

“Our mission is to create potential for saving lives. We want to be in a forefront producing reliable material and scientific knowledge to explore the biomedical potential of blood EVs. We have developed isolation, purification and functional characterization of extracellular vesicles from blood. Together with our partners in national EV consortium (EVE), FRCBS has reached its set goals and is ready to take the step towards EV production. For this step we need a partner that we can trust on quality when moving forward. For us the obvious choice was HansaBioMed” says Dr Saara Laitinen, R&D manager at FRCBS and the leader of the country’s National EV Consortium.

HansaBioMed Life Sciences contact details:
Paolo Guazzi, Chief Operating Officer
paolo.guazzi@hansabiomed.eu
+372 6561996

Finnish red Cross Blood Service (FRCBS) contact details:
Saara Laitinen, R&D manager
Saara.Laitinen@veripalvelu.fi
+358 29-300 1695